SYGGF - Synairgen's inhaled interferon beta treatment included in US NIH ACTIV-2 trial for COVID-19

UK-based nano cap Synairgen (SYGGF) announces that its inhaled interferon beta treatment has been included in the US NIH ACTIV-2 trial in COVID-19 outpatients.ACTIV partnership is funded by "Operation Warp Speed", led by the US Government’s Department of Health and Human Services and designed to speed up the development of the most promising treatments and vaccine candidates for COVID-19.ACTIV-2/A5401 is an adaptive, randomised, blinded, placebo-controlled phase II/III trial in patients with COVID-19 not yet requiring hospitalisation.Synairgen also started dosing in an international 610 patient Phase III trial on 12 January 2021, assessing the efficacy of inhaled interferon beta in hospitalised patients with COVID-19, it said.

For further details see:

Synairgen's inhaled interferon beta treatment included in US NIH ACTIV-2 trial for COVID-19